ERBB2 and neoplasm: Similarly to other studies, chemotherapy was more often recommended to women with HER2-positive and triple-negative tumours because of the higher recurrence risk associated with such tumours, the proven effectiveness of anti-HER2 therapies, and the lack of any alternative systemic treatment options for triple-negative diseases [18,21].